Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Size Forecast From 2026 To 2030: Key Industry Trends
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Revenue Growth On Track For A 29.6% CAGR Through 2030
The artificial intelligence (AI)-driven rare disease patient finder market has expanded considerably in recent years. Its size is expected to increase from $1.62 billion in 2025 to $2.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 29.9%. The historical growth of this market is attributable to the greater availability of electronic health records, the early integration of data analytics into clinical research, the enlargement of genomic databases, a heightened emphasis on orphan diseases, and the initial deployment of AI in trial recruitment.
The artificial intelligence (AI)-driven rare disease patient finder market size is projected to experience significant expansion over the next few years. It is expected to reach $5.95 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 29.6%. This growth during the forecast period is attributable to increasing investments in precision medicine research, rising demand for faster clinical trial enrollment, the expansion of real-world evidence analytics, growing collaboration between healthcare and life sciences firms, and increasing regulatory support for rare disease innovation. Major trends anticipated for the forecast period include the increasing use of AI-based patient identification algorithms, rising integration of multi-source health data, growing automation of clinical trial recruitment, the expansion of precision patient matching platforms, and an enhanced focus on rare disease research enablement.
Get A Free Sample Report With In-Depth Market Insights:
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Demand Drivers: What’s Powering Industry Growth?
The artificial intelligence (AI)-driven rare disease patient finder market is expected to experience growth driven by the rising adoption of digital health and telemedicine. Digital health encompasses the application of technology, software, and electronic instruments to monitor, manage, and improve an individual’s health and wellness. Telemedicine refers to the provision of healthcare services remotely through telecommunications technology, including video calls, mobile applications, and online platforms. The increased acceptance of digital health and telemedicine is attributed to patients and providers seeking convenient, time-efficient, and easily accessible healthcare solutions. The artificial intelligence (AI)-driven rare disease patient finder aids digital health and telemedicine by accurately identifying patients, facilitating remote monitoring, enabling timely virtual consultations, and delivering personalized care. For instance, in November 2025, the Organisation for Economic Co operation and Development, an intergovernmental organization based in France, indicated that OECD countries had progressed in broadening access to EHRs. In 2024, the average availability of online digital health services reached 82%, a rise from 79% in 2023 among countries with comparable data. Thus, the growing acceptance of digital health and telemedicine is propelling the expansion of the artificial intelligence (AI)-driven rare disease patient finder market.
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Segments: Where Is Growth Concentrated?
The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented –
1) By Component: Software, Services
2) By Deployment Mode: Cloud-Based, On-Premises
3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications
4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users
Subsegments:
1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System
2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the AI-driven rare disease patient finder market are focusing on developing technological advancements, specifically precision patient recruitment solutions. This effort aims to improve the accuracy, speed, and efficiency of identifying suitable patients for rare disease clinical trials, while simultaneously reducing recruitment timelines and enhancing trial success rates. A precision patient recruitment solution is a technology-driven method that leverages advanced algorithms and real-world data to precisely identify and engage patients who meet specific clinical trial eligibility criteria. For instance, in April 2024, Citeline, a US-based business intelligence and data analytics company, launched Citeline PatientMatch. This platform integrates sophisticated algorithms with comprehensive real-world data, including lab results, biomarkers, and electronic medical records from over 400 hospitals and health systems. Its goal is to assist sponsors and investigators in identifying eligible patients for clinical trials promptly and efficiently, streamline enrollment, and support diverse and complex study protocols across multiple therapeutic areas.
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Key Participants And Competitive Landscape
Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., RareSum Inc.
View The Full Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:
Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-driven rare disease patient finder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
